SGNTV-002: Open Label Phase 2 Study of Tisotumab Vedotin for Patients with Platinum-Resistant Ovarian Cancer with a Safety Run-in of a Dose-Dense Regimen

Administered By

Contributors

Start/End

  • January 11, 2019 - 2024-01-31